Brookline downgraded CervoMed (CRVO) to Hold from Buy and suspended the firm’s price target on the shares following the failure of the company’s Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
Questions or Comments about the article? Write to editor@tipranks.com